Hot off the presses: Click here to see the Scientific American issue on Alzheimer’s disease and brain health!
Leading an Unprecedented Global Response to Alzheimer's
We are uniting leading organizations worldwide to build an innovation ecosystem that will accelerate breakthroughs, develop and scale promising solutions and equip every healthcare system to end Alzheimer's disease everywhere.
The Challenge
3x
By 2050, the number of people living with dementia will triple to 139 million.
75%
Globally, 3 out of 4 people with dementia are never even diagnosed, much less treated.
$1.3 trillion
Every year, dementia costs the global economy more than $1.3 trillion. This number will increase by up to nine times from 2020 to 2050.
Our Programs
Alzheimer’s recognizes no borders - neither can our solutions.
-
Global Cohorts
Diversifying Data to Unlock Breakthroughs
Scientific discovery starts with high-quality data. But 90% of current genetic analysis comes from just 10% of the world's population. DAC is building global cohorts to advance understanding of Alzheimer's among diverse populations. This data will provide the foundation for identifying new biomarkers and developing targeted treatments for people worldwide.
-
Global Clinical Trials
Linking the Best Science to Speed Innovation
Progress against Alzheimer's requires faster, less costly clinical trials. DAC is building a global clinical trial network and technology platform that will link trial sites around the world. This will drive innovation by reducing the time and cost of clinical trials, connecting researchers worldwide and accelerating drug development for people in all communities.
-
Healthcare System Preparedness
Delivering Solutions to People Everywhere
Innovations only make an impact if they reach the people who need them. DAC is investing in healthcare systems and solution providers to improve rates of early, accurate diagnosis and to ensure healthcare systems worldwide are prepared to deliver new innovations that enter the market.
About Us
Our Beginning
The idea for developing a global mechanism of action was first raised at the 2019 Lausanne Workshop. It was taken forward at the World Economic Forum's Annual Meeting in 2020, where a diverse group of private-sector executives, government leaders and NGOs came together with a singular goal: How can we mount a global response to Alzheimer's by orchestrating game-changing solutions to end the suffering, financial burden and stigma around this disease?
Led by the World Economic Forum (WEF) and The Global CEO Initiative on Alzheimer's Disease (CEOi), the Davos Alzheimer's Collaborative (DAC) is investing over $700 million over 6 years to accelerate innovation in drug development and transform the way healthcare systems diagnose and treat Alzheimer's for all people in all places.
-
![Klaus Schwab]()
“The Davos Alzheimer’s Collaborative’s progress signals the importance of a collective global response to this growing crisis. Like other initiatives incubated at the World Economic Forum, such as the Global Alliance for Vaccines and Immunization (GAVI) and the Coalition for Epidemic Preparedness Innovations (CEPI), DAC is bringing new cooperative energy to the fight against Alzheimer’s.”
・Klaus Schwab・
Founder & Executive Chairman of the World Economic Forum -
![George Vradenburg]()
“Alzheimer’s is our silent pandemic and the biggest public health crisis of the 21st century, requiring this multi-stakeholder initiative to catalyze coordinated global action at the scope and scale of the response to AIDS, cancer and climate change.”
・George Vradenburg・
Convener of the Davos Alzheimer’s Collaborative; Founder of The Global CEO Initiative on Alzheimer’s Disease -
![Margaret Chan]()
“National leaders must create a global mechanism – like CEPI and COVAX – to respond to the worldwide dementia pandemic. The Davos Alzheimer’s Collaborative is that global mechanism, bringing together national governments, industry leaders, top scientists, leading NGOs and patient-led organizations, including, importantly, from low- and middle-income countries. The time to act is now.”
・Margaret Chan・
Former Director General of the WHO; Dean of the Vanke School of Public Health, Tsinghua University, People’s Republic of China -
![Dr. Freda Lewis-Hall]()
“I believe in DAC’s mission to unite experts and organizations with diverse skills and perspectives through a common focus on delivering the results that matter most for individuals, families and communities affected by this challenging disease. While we face a long fight ahead against Alzheimer’s, DAC ensures that no one is fighting alone.”
・Dr. Freda Lewis-Hall・
Founding Board Member, DAC and former Chief Patient Officer, Executive Vice President and Chief Medical Officer, Pfizer
